Revance Therapeutics (RVNC) Goldman Sachs 45th Annual Global Healthcare Conference summary

Strategic priorities and recent performance

• Focused on successful rollout and market embedding of DAXXIFY, with Q1 unit growth of 107% year-over-year.

• Adjusted pricing and messaging for DAXXIFY to align with market feedback, now positioned competitively.

• RHA filler line share increased to nearly 10% in Q1, with ongoing account activation efforts.

• Therapeutics franchise launched with first approval in cervical dystonia and strong initial clinician feedback.

• International expansion underway, with anticipated product approvals in China and supply chain maturation.

Market trends and competitive landscape

• Aesthetics market remains underpenetrated in the U.S., with strong long-term growth drivers and a shift toward natural results.

• Economic sensitivity observed more in fillers than toxins, with Q1 filler softness but improving Q2 trends.

• Practices typically carry multiple toxin brands, with differentiation and innovation driving adoption.

• DAXXIFY's non-refrigeration feature offers practical advantages for smaller practices.

Commercial strategy and account penetration

• Shifted DAXXIFY pricing to be on par with competitors, broadening appeal across account types.

• Currently in 7,500 accounts, with 3,500 ordering DAXXIFY; targeting 5-6% market share by year-end.

• Two-thirds of revenue comes from existing accounts, with increasing focus on new account activation.

• Loyalty programs to be practice-linked, with consumer activation initiatives planned for the second half of the year.